colorectal cancer
Conditions
Interventions
UFT 300mg per m2 per day and LV 75mg per day for 28 days Oxaliplatin:85mg/m2 day1,15 every 5-weeks for 3-cycle After this therapy, followed by UFT/LV until 1 year
Sponsors
Toho University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically proved Adenocarcinoma of colon or rectum. 2) Stage IIIA/IIIB of colon or rectum 3)>=D2 lymph node dissection 4)Pathological curability is A or B 5)Age:20-80 years old 6)Performance status 0-1 7)Without prior anti-tumor therapy 8)Adequate organ function 9)Able to start between 8 weeks after surgery 10)The case can eat 11)Written IC
Exclusion criteria
Exclusion criteria: 1)Multiple malignancies within five years 2) Other severe complications, such as pulmonary emphysema, pulmonary fibrosis, hyper pulmonary emphysema,paralysis intestinal, intestinal obstruction, uncontrolable diabetes, cirrhosis, uncontrollable hypertension, myocardial infarction within six months, angina. 3)Diarrhea 4) Pregnant 5)Evidence of psychiatric disability interfering with enrollment to clinical trial 6)Patients judged inappropriate for this study by physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients ratio with completion of adjuvant TEGAFOX therapy | — |
Countries
Japan
Contacts
Public ContactKoike Junichi
Toho University School of Medicine Division of general and gastroenterological surgery, Department of Surgery (Omori)
Outcome results
None listed